Objectives: The aim of this study was to assess whether the duration of preoperative benign prostatic hyperplasia (BPH) medication would affect the pressure flow study (PFS) parameters and the outcome of prostate surgery or not. Material and methods: A retrospective study involving patients with LUTS/BPH aged 50 years or older who were compliant with BPH medications. PFS was performed prior to prostate surgery to determine BOO degree and detrusor overactivity. The efficacy of prostate surgery was determined at 3 and 6 months after surgery using the I-PSS, QOL index, Q-max, and PVR. Patients were categorized into group A, who received treatment for 12 months or less, and group B, who received the treatment for 12 months or more. The categorization starts once the patient prefers surgical intervention. Results: A total of 114 patients were enrolled, 50 in group A and 64 patients in group B. The mean duration, in months, of medical treatment was 9.52 ± 2.24 and 22.50 ± 4.35 in group A and group B, respectively. Pdet@Qmax is significantly (p = 0.02) higher in patients of group B (63.85 ± 11.34 vs. 94.75 ± 19.53). The detrusor overactivity amplitude is slightly higher in group A (36.42 ± 37.27 vs. 16.42 ± 28.38) (p = 0.3). The mean I-PSS, Q-max, and PVR at 1, 3, and 6 months were comparable between the groups. Conclusion: After 24 months of BPH medical treatment, no profound PFS changes that may affect the decision of prostate surgery were observed. Patients who completed 24 months of medical treatment were safe as regards to detrusor muscle contractility with no urge to undergo prostate surgery earlier.

Keywords:
Benign prostatic hyperplasia, Pressure flow study, Detrusor overactivity, Benign prostatic hyperplasia medication duration
1.
Rollema
 
HJ
,
Van Mastrigt
 
R
.
Improved indication and followup in transurethral resection of the prostate using the computer program CLIM: a prospective study
.
J Urol
.
1992
;
148
(
1
):
111
–
6
.
https://doi.org/10.1016/s0022-5347(17)36527-8
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Robertson
 
AS
,
Griffiths
 
C
,
Neal
 
DE
.
Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction
.
J Urol
.
1996
;
155
(
2
):
506
–
11
.
https://doi.org/10.1097/00005392-199602000-00027
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Neal
 
DE
,
Ramsden
 
PD
,
Sharples
 
L
,
Smith
 
A
,
Powell
 
PH
,
Styles
 
RA
,  
Outcome of elective prostatectomy
.
BMJ
.
1989
;
299
(
6702
):
762
–
7
.
https://doi.org/10.1136/bmj.299.6702.762
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Jensen
 
KM
,
Jørgensen
 
JB
,
Mogensen
 
P
.
Urodynamics in prostatism. II. Prognostic value of pressure-flow study combined with stop-flow test
.
Scand J Urol Nephrol Suppl
.
1988
;
114
:
72
–
7
.
Google Scholar
PubMed
 
5.
Javlé
 
P
,
Jenkins
 
SA
,
Machin
 
DG
,
Parsons
 
KF
.
Grading of benign prostatic obstruction can predict the outcome of transurethral prostatectomy
.
J Urol
.
1998
;
160
(
5
):
1713
–
7
.
https://doi.org/10.1016/s0022-5347(01)62391-7
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Machino
 
R
,
Kakizaki
 
H
,
Ameda
 
K
,
Shibata
 
T
,
Tanaka
 
H
,
Matsuura
 
S
,  
Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy
.
Neurourol Urodyn
.
2002
;
21
(
5
):
444
–
9
.
https://doi.org/10.1002/nau.10057
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
McConnell
 
JD
,
Roehrborn
 
CG
,
Bautista
 
OM
,
Andriole
 
GL
 Jr,
Dixon
 
CM
,
Kusek
 
JW
,  
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
.
N Engl J Med
.
2003
;
349
(
25
):
2387
–
98
.
https://doi.org/10.1056/NEJMoa030656
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Sitdykova
 
ME
,
Tsyplakov
 
DE
,
Sitdykov
 
EN
,
Nurtdinov
 
AR
.
Rationale of pharmacotherapy duration in patients with benign prostatic hyperplasia (a clinical-morphological study)
.
Urologiia
.
2017
(
2
):
42
–
7
.
Google Scholar
 
9.
Lin
 
VC
,
Liao
 
CH
,
Kuo
 
HC
.
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study
.
Urology
.
2014
;
83
(
2
):
416
–
21
.
https://doi.org/10.1016/j.urology.2013.09.036
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
van der Worp
 
H
,
Jellema
 
P
,
Hordijk
 
I
,
Lisman-van Leeuwen
 
Y
,
Korteschiel
 
L
,
Steffens
 
MG
,  
Discontinuation of alpha-blocker therapy in men with lower urinary tract symptoms: a systematic review and meta-analysis
.
BMJ Open
.
2019
;
9
(
11
):
e030405
.
https://doi.org/10.1136/bmjopen-2019-030405
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Tanaka
 
Y
,
Masumori
 
N
,
Itoh
 
N
,
Furuya
 
S
,
Nishizawa
 
O
,
Tsukamoto
 
T
.
Symptomatic and urodynamic improvement by oral distigmine bromide in poor voiders after transurethral resection of the prostate
.
Urology
.
2001
;
57
(
2
):
270
–
4
.
https://doi.org/10.1016/s0090-4295(00)00924-9
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Gotoh
 
M
,
Yoshikawa
 
Y
,
Kondo
 
AS
,
Kondo
 
A
,
Ono
 
Y
,
Ohshima
 
S
.
Prognostic value of pressure-flow study in surgical treatment of benign prostatic obstruction
.
World J Urol
.
1999
;
17
(
5
):
274
–
8
.
https://doi.org/10.1007/s003450050145
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
Zhong
 
P
,
Zhao
 
YR
,
Qiao
 
BM
,
Yang
 
FJ
,
Zhu
 
Y
,
Yang
 
ZQ
,  
Comparison of two numerical parameters to assess detrusor contractility in prognosing short-term outcome after transurethral resection of the prostate
.
Urol Int
.
2020
;
104
(
5
–
6
):
361
–
6
.
https://doi.org/10.1159/000503331
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.